Stryker buys out of OP-1 royalties to Curis:
This article was originally published in Clinica
Stryker (Kalamazoo, Michigan) is to pay a one-off cash sum of $14m to Curis (Cambridge, Massachusetts) to release itself from the obligation to pay royalties on future sales of its osteogenic protein-1 bone growth factor (OP-1). Stryker will amortise the payment over the next 15 years. The agreement allows Curis to reduce royalty payments it may owe Stryker for sales of the product, which it calls BMP-7 (bone morphogenic protein), in indications other than orthopaedics and dental (eg, kidney disease).
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.